Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...
Hosted on MSN23d
Novartis buys Blackstone's Anthos for up to $3.1 billion(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...
U.S. FIRMS In addition to the CEOs of Qualcomm, FedEx, Standard Chartered, Citadel, Bain and KPMG, Pfizer CEO Albert Bourla, Blackstone's CEO and co-founder Stephen Schwarzman, Chubb CEO Evan ...
Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...
Mitsubishi Tanabe Pharma and bluebird bio were both bought by investors during the month, while private equity firms ...
February 11, 2025 Novartis buys Blackstone's Anthos for up to $3.1 billion Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...
The medicine was first licensed from Novartis by Blackstone Life Sciences in 2019, and the company invested $250 million in clinical trials to support its development. To acquire complete control ...
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback